Version history

{
  "session_id": "sess-hyp-0bb6b3633d42",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "llm",
  "action": "synthesize",
  "content": "\n\n# Scientific Synthesis & Evaluation\n\n## Summary of Prior Debate\n\n**THEORIST (Round 1)** presented mechanistic rationale supporting the hypothesis, likely emphasizing TREM2's established role in microglial survival, phagocytosis, and the progression from homeostatic to disease-associated microglia (DAM) states. The stage-specific model provides a framework linking molecular changes to clinical decline.\n\n**SKEPTIC (Round 2)** arguments were not provided in this synthesis request, though critical concerns likely include: (1) the bidirectional nature of TREM2 signaling—where both loss and gain may be detrimental, (2) potential confounders in human post-mortem studies showing TREM2 expression changes, and (3) whether downregulation is cause or consequence of neurodegeneration.\n\n**DOMAIN_EXPERT (Round 3)** provided a druggability assessment confirming TREM2 as a \"highly druggable target\" with strong genetic validation, though noting the specific mechanistic claim requires scrutiny.\n\n---\n\n## Dimension Scores\n\n| Dimension | Score | Rationale |\n|-----------|-------|-----------|\n| **Mechanistic Plausibility** | 0.78 | TREM2's role in microglial phagocytosis and survival is well-established. The stage-specific model is mechanistically coherent, though causality (downregulation → dysfunction vs. dysfunction → downregulation) remains uncertain. The DAM transition model has experimental support, but precise temporal dynamics require clarification. |\n| **Evidence Strength** | 0.72 | Strong genetic evidence (TREM2 R47H and other loss-of-function variants increasing AD risk). Solid preclinical data in mouse models. Human post-mortem data showing",
  "tokens_used": "414",
  "persona_id": "persona-synthesizer"
}